AKBA
Akebia Therapeutics, Inc.
0.8148$
-6.7%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -17.0% | -4.1% | -59.6% | -23.1% | -17.9% | -9.6% | -23.7% | 35.8% | 47.8% | 54.0% | -39.6% | 7.2% | 19.0% | |
| 22.4% | 16.7% | 28.8% | 21.6% | 25.0% | 20.1% | 0.5% | 0.5% | 0.5% | 0.6% | 0.6% | 1.2% | 0.7% | |
| 4.3% | 2.7% | 7.2% | 4.7% | 4.4% | 3.6% | 3.8% | 4.3% | 5.5% | 5.6% | 6.9% | 6.6% | 6.1% | |
| -10.0% | -28.8% | -46.5% | -31.3% | -20.5% | -6.9% | -51.8% | 8.2% | 32.7% | 38.0% | -45.8% | 7.7% | 9.3% | |
| 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.2% | 0.1% | 0.3% | 0.1% | 2.2% | 0.6% | |
| – | – | – | -0.1% | 0.0% | 0.0% | 0.3% | -0.2% | -0.1% | -13.7% | -0.1% | -8.3% | -5.5% | |
| – | – | -2.3% | – | 2.0% | – | -0.1% | – | 0.1% | -0.2% | 0.0% | – | – | |
| – | – | – | – | 0.0% | 0.0% | 16.6% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| 0.1% | -2.3% | 56.7% | 17.5% | 3.3% | 48.0% | 130.7% | 2.8% | 1.9% | -8.4% | -1.7% | -13.3% | -5.1% | |
| -16.9% | -6.4% | -2.9% | -5.6% | -14.6% | 38.4% | 107.3% | 38.3% | 49.6% | 31.9% | -41.5% | -14.4% | 8.3% | |
| -17.0% | -4.1% | -59.6% | -23.1% | -17.9% | -9.6% | -23.7% | 35.6% | 47.7% | 53.7% | -39.6% | 5.0% | 18.4% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.